Takeda Pharmaceutical Price to Free Cash Flow Ratio 2010-2024 | TAK

Takeda Pharmaceutical current price to free cash flow ratio as of January 22, 2025 is 9.92.

  • Takeda Pharmaceutical average price to free cash flow ratio for 2024 was 10.45, a 25.75% decline from 2023.
  • Takeda Pharmaceutical average price to free cash flow ratio for 2023 was 8.31, a 59.5% increase from 2022.
  • Takeda Pharmaceutical average price to free cash flow ratio for 2022 was 5.21, a 3.78% increase from 2021.

Price to free cash flow ratio can be defined as

Takeda Pharmaceutical Price to Free Cash Flow Ratio 2010-2024 | TAK

  • Takeda Pharmaceutical average price to free cash flow ratio for 2024 was 10.45, a 25.75% decline from 2023.
  • Takeda Pharmaceutical average price to free cash flow ratio for 2023 was 8.31, a 59.5% increase from 2022.
  • Takeda Pharmaceutical average price to free cash flow ratio for 2022 was 5.21, a 3.78% increase from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$74.8B
Chugai Pharmaceutical (CHGCY)$70.2B
Sandoz Group AG (SDZNY)$19.6B
Merck (MKKGY)$18.8B
Astellas Pharma (ALPMY)$17.3B
United Therapeutics (UTHR)$16B
Neurocrine Biosciences (NBIX)$14.5B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.1B
Orion OYJ (ORINY)$7.2B
Stevanato Group S.p.A (STVN)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Corcept Therapeutics (CORT)$5.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Grifols, S.A (GRFS)$5B
Ionis Pharmaceuticals (IONS)$5B
Crinetics Pharmaceuticals (CRNX)$3.5B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Recursion Pharmaceuticals (RXRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Soleno Therapeutics (SLNO)$2B
Centessa Pharmaceuticals (CNTA)$2B
Hypermarcas (HYPMY)$1.9B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Evotec AG (EVO)$1.5B
Dyne Therapeutics (DYN)$1.4B
Xencor (XNCR)$1.3B
Guardian Pharmacy Services (GRDN)$1.3B